Emerging drugs for non-alcoholic steatohepatitis

Author： Tomeno Wataru   Yoneda Masato   Imajo Kento   Ogawa Yuji   Kessoku Takaomi   Saito Satoru   Eguchi Yuichiro   Nakajima Atsushi  

Publisher： Informa Healthcare

ISSN： 1472-8214

Source： Expert Opinion on Emerging Drugs, Vol.18, Iss.3, 2013-09, pp. : 279-290

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Emerging drugs for non-alcoholic fatty liver disease

By Federico Alessandro   Niosi Marco   Vecchio Blanco Camillo Del   Loguercio Carmela  

Expert Opinion on Emerging Drugs, Vol. 13, Iss. 1, 2008-03 ,pp. : 145-158

Informa Healthcare

Access to resources Recommend Favorite

Evolving therapies for non-alcoholic steatohepatitis

By Tilg Herbert   Moschen Alexander R  

Expert Opinion on Drug Discovery, Vol. 9, Iss. 6, 2014-06 ,pp. : 687-696

Informa Healthcare

Access to resources Recommend Favorite

Treatment of non-alcoholic fatty liver disease with focus on emerging drugs

By Marchesini Giulio   Moscatiello Simona   Agostini Federica   Villanova Nicola   Festi Davide  

Expert Opinion on Emerging Drugs, Vol. 16, Iss. 1, 2011-03 ,pp. : 121-136

Informa Healthcare

Access to resources Recommend Favorite

Cyclophosphamide/dexamethasone: Non-alcoholic steatohepatitis: case report

By  

Reactions Weekly, Vol. 1, Iss. 1233, 2009-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

Role of microRNAs in Non-Alcoholic Steatohepatitis

By  

Current Pharmaceutical Design, Vol. 16, Iss. 17, 2010-06 ,pp. : 1952-1957

Bentham Science Publishers

Access to resources Recommend Favorite